Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck's Lantus Copy Lusduna Poised For US Market Pending Litigation

20 Jul 2017

• By Jessica Merrill

Diabetes

Related Content

UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense

22 Sep 2016

FDA Makes It Official With Basaglar Approval For Diabetes

16 Dec 2015

Sanofi Settlement With Lilly Paves The Way For Biosimilar Lantus

28 Sep 2015

Related Companies

Merck & Co., Inc.

Samsung Bioepis Co., Ltd.

Sanofi

Eli Lilly and Company

Boehringer Ingelheim GmbH

Additional Topics

Biosimilars Approvals Commercial Metabolic Disorders BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.